Shots:

• The P-III ETHOS study involves assessing of Breztri Aerosphere (budesonide/glycopyrronium/formoterol fumarate 320/14.4/9.6mcg) vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate 14.4/9.6mcg) and PT009 (budesonide/formoterol fumarate 320/9.6mcg) in symptomatic patients with mod. to sev. COPD
• The P-III ETHOS study resulted in meeting its 1EPs i/e- reduction in the rate of mod./sev. exacerbations at both standard & half dose of budesonide. The P-III ETHOS study follows KRONOS study which also resulted in reduction of exacerbation in COPD patients
• Breztri Aerosphere is an approved triple combination therapy in Japan and is under regulatory review in the US- China and EU and Bevespi Aerosphere (FD) is dual bronchodilator- administered in a pressurized metered-dose inhaler utilizing Aerosphere delivery technology

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca